Thermo Fisher Scientific (TMO) to Release Quarterly Earnings on Thursday

Key Points

• Thermo Fisher will report Q1 2026 results before the market opens on Thursday, April 23 at 8:30 AM ET; analysts expect EPS of $5.25 and revenue of $10.8606 billion.
• The company beat the prior quarter (EPS $6.57 vs. $6.45 estimate; revenue $12.22B) and analysts forecast $23 EPS for the current fiscal year and $26 for next, with a consensus rating of Moderate Buy and a $631.25 price target.
• Thermo Fisher raised its quarterly dividend to $0.47 (annualized $1.88) from $0.43, yielding 0.4%, and corporate insiders including the CEO have recently sold shares.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) is anticipated to announce its Q1 2026 results before the market opens on Thursday, April 23rd. Analysts expect the company to announce earnings of $5.25 per share and revenue of $10.8606 billion for the quarter. Investors may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, April 23, 2026 at 8:30 AM ET.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, beating the consensus estimate of $6.45 by $0.12. The business had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The company's revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the business earned $6.10 earnings per share. On average, analysts expect Thermo Fisher Scientific to post $23 EPS for the current fiscal year and $26 EPS for the next fiscal year.

Thermo Fisher Scientific Trading Up 0.8%

Shares of Thermo Fisher Scientific stock opened at $531.69 on Thursday. The firm has a market capitalization of $197.59 billion, a PE ratio of 29.97, a price-to-earnings-growth ratio of 2.82 and a beta of 0.97. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. The firm's 50 day moving average is $502.46 and its 200 day moving average is $550.12. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $643.99.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.60%.

Analyst Ratings Changes

Several research analysts have recently issued reports on TMO shares. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, February 28th. DZ Bank started coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They set a "buy" rating and a $610.00 price target for the company. TD Cowen lowered their price target on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a report on Friday, January 30th. Weiss Ratings restated a "hold (c)" rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Finally, Stifel Nicolaus increased their price objective on Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a "buy" rating in a report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $631.25.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares of the company's stock, valued at $63,499,170. This represents a 3.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. This trade represents a 1.89% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.33% of the company's stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of institutional investors and hedge funds have recently made changes to their positions in TMO. Sunbelt Securities Inc. increased its stake in Thermo Fisher Scientific by 5.3% in the 4th quarter. Sunbelt Securities Inc. now owns 573 shares of the medical research company's stock valued at $332,000 after buying an additional 29 shares during the last quarter. Evansbrook LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $215,000. Birchwood Financial Partners Inc. purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $29,000. Strive Financial Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $2,209,000. Finally, Blue Sparrow LLC DE bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $16,167,000. Institutional investors own 89.23% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.